Cardiovascular Outcomes of Hypogonadal Men Receiving Testosterone Replacement Therapy: A Meta-analysis of Randomized Controlled Trials
Authors' conclusion
Previous research on TRT and cardiovascular events, with comparisons to studies like the Testosterone Trials and the studies conducted by Vigen et al, Finkle et al, Layton et al, and Wallis et al, is provided. The significance of the systematic review and meta-analysis approach is emphasized, particularly its exclusive focus on hypogonadal patients.
Study context
- Population
- Hypogonadal men
- Participants
- 10,941 men26 RCTs
- Comparison
- Testosterone replacement therapy (TRT) vs control
- Outcome
- Cardiovascular outcomes: all-cause mortality, cardiovascular-related mortality, MI, stroke, congestive HF, AF, PE and venous thrombosis
Methodological detailssensitivity analysis, publication bias assessment, meta-regression
- Sensitivity analysis
- Publication bias assessment
- Meta-regression
Pooled result
As reported in the abstract
All-cause mortality, cardiovascular-related mortality, MI, stroke, congestive HF, AF, PE, venous thrombosis
- No statistically significant differences between TRT and control in these clinical outcomes
Further pooled results
Robustness of findings
- Sensitivity analysis and publication bias assessment supported the robustness of the findings
Meta-regression on covariates
- No significant associations between clinical outcomes and age, diabetes, hypertension, dyslipidemia or smoking
Original publication
Cardiovascular Outcomes of Hypogonadal Men Receiving Testosterone Replacement Therapy: A Meta-analysis of Randomized Controlled Trials. Endocr Pract. Published 4 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →